{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107984","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.172414+00:00","generated_at":"2026-05-17T13:55:06.578131+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years","bullets":["Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.","Gross margin 50.9%, highest since Q3 2019, up from 47.0% in Q2 2024.","Adjusted EBITDA positive $0.1M, first since Q2 2019, vs -$6k in Q2 2024.","Cash balance $0.9M at quarter end, up from $0.5M at end of 2024.","CEO cites state regulatory pressure for sales decline; pushing M&A and new products."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107984","json":"https://secwatch.observer/filing/0000950170-25-107984.json","markdown":"https://secwatch.observer/filing/0000950170-25-107984.md","text":"https://secwatch.observer/filing/0000950170-25-107984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000095017025107984/0000950170-25-107984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000095017025107984/cvsi-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:55:06.578131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}